Wed, Nov 26, 2014, 6:27 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Osiris Therapeutics, Inc. Message Board

vincenzo01 5 posts  |  Last Activity: Nov 7, 2014 8:29 AM Member since: Apr 3, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Link To This Article:
    Osiris Therapeutics Announces Third Quarter 2014 Financial Results: Revenue up 29% and Company Turned Profitable
    Date : 11/07/2014 @ 8:00AM
    Source : Business Wire
    Stock : Osiris Therapeutics, Inc. (MM) (OSIR)
    Quote : 13.88 0.0 (0.00%) @ 8:00AM

    Osiris Therapeutics Announces Third Quarter 2014 Financial Results: Revenue up 29% and Company Turned Profitable
    Osiris Therapeutics, Inc. (MM) (NASDAQ:OSIR)
    Intraday Stock Chart

    Today : Friday 7 November 2014
    Click Here for more Osiris Therapeutics, Inc. (MM) Charts.

    Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedic and sports medicine, announced today its financial results for the third quarter of 2014.

    Highlights and Recent Developments

    Increased product revenue for the quarter to $17.2 million - a 29% increase over previous quarter and 150% increase over the same period last year. Held gross margin steady at 78% for the first three quarters of fiscal 2014.
    Completed the quarter with income from continued operations of $710,000 or $0.02 per share.
    Increased Medicare coverage from 10 to 29 states, representing an increase from 27% to 72% of Medicare-insured lives compared to previous quarter.
    Entered into an exclusive distribution partnership for our cartilage regenerating product Cartiform® with Arthrex Inc., the leader in sports medicine.
    Obtained final letter from FDA confirming the resolution of the issues of the Untitled Letter of September 2013 and submitted the confirmatory Phase III clinical trial protocol for chronic wounds to medical reviewer. Osiris is seeking BLA approval for our amnion/chorion products for additional claims and indications.
    Prochymal® submitted to Japanese Health Authorities by our partner Mesoblast, seeking approval for pediatric and adult Graft-versus-Host Disease.

    “This quarter represent

  • vincenzo01 vincenzo01 Oct 27, 2014 8:18 AM Flag

    Correction: Henry was and continues to be the President. Joe, as CEO, has completed his work and is now longer employed in that position. Henry is the transitional CEO until the BOD appoints a new CEO.

  • the board of directors decided that in the best interests of XXII as the company transitions into a new phase of promoting and selling products, Henry will be the new President. Different skills are called for as XXII moves into this next stage of development.

  • This is an approximation based on memory, but last quarter, ending about 30 June, OSIR earnings came in at a $66,000 loss due to a substantial decline in the value of its Mesoblast stock holding. I think it was a roughly $2.5 million decline in the value of MSB.AX. Since then, MSB.AX has actually closed the most recent quarter a little higher. Based on eye-balling its chart on Yahoo, the MSB value on 30 June was about $4.20 and on 30 Sept it was higher than that. So OSIR earnings for the most recent qtr should a bit higher based on the increase of th evalue of the MSB shares OSIR holds.

  • Reply to

    Investment Account

    by ozark580 Sep 2, 2014 8:52 PM
    vincenzo01 vincenzo01 Sep 3, 2014 8:19 AM Flag

    Footnote: My recollection is that for the last quarter, Osiris reported a loss of about $2.5 million on the decline in the value of the Mesoblast has owned since the sale of Prochymal. That paper loss changed the last quarter's bottom line from being a strong gain to being a tiny loss of $66,000. I hope our Treasurer Phil J can do some creative accounting for the current quarter so our bottom line is not sky high profit. Perhaps that's a fine problem to have.

13.50+0.01(+0.07%)Nov 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.